Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study
Chong Wang(Jilin University), Junqi Niu(Jilin University), Guicheng Wu(Fujian Medical University), Yanhang Gao(Jilin University), Haibing Gao(Fujian Medical University), George Zhang(Shanghai Research Institute of Building Sciences (China)), Xiu‐Ping Yan(Jiangnan University), Guoqiang Zhang(Johnson & Johnson (United States)), Guoping Li(North Sichuan Medical University), Wenqiang Wu, Qin Ning(Huazhong University of Science and Technology), Tianxiang Zhang(Harbin Normal University), Fei Kong(Shanghai Jiao Tong University), Bei Zhong(Guangzhou Medical University), Dachuan Cai(Dalian Medical University), John Mao, Zhijun Su(Fujian Medical University)
Cited by 7
Related Papers
Bottom-up synthesis of chiral covalent organic frameworks and their bound capillaries for chiral separation
|Nature Communications|2016|500
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Acute liver failure: mechanisms of immune-mediated liver injury
|Liver International|2010|280